Daiichi Sankyo Aims to File Antibody Drug Conjugate DS-8201 in 2020 for HER2-Positive Breast Cancer, Stomach Cancer

Antoine Yver, Global Head of Oncology R&D Daiichi Sankyo aims to file marketing applications in 2020 for its anti-HER2 antibody drug conjugate (ADC) DS-8201 for HER2-positive breast and stomach cancer, the company’s global oncology R&D head revealed on December 13...read more